Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, Jaya Sri Konakanchi, Gregory Maggio, Roopa Sethi
{"title":"注射部位对缓释丁丙诺啡(亚locade®)治疗阿片类药物使用障碍的反应。","authors":"Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, Jaya Sri Konakanchi, Gregory Maggio, Roopa Sethi","doi":"10.17161/kjm.vol15.17931","DOIUrl":null,"url":null,"abstract":"302 Injection Site Reaction to ExtendedRelease Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration Elizabeth Weesner1, Hosain Ghassemi1, Iryna Salapenka, M.D.2, Jaya Sri Konakanchi, MBBS1, Gregory Maggio, D.O.2, Roopa Sethi, M.D.2 1University of Kansas School of Medicine, Kansas City, KS 2University of Kansas Health System, Kansas City, KS Department of Psychiatry and Behavioral Sciences Received April 21, 2022; Accepted for publication May 25, 2022; Published online Aug. 22, 2022 https://doi.org/10.17161/kjm.vol15.17931","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"302-304"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/34/15-302.PMC9409986.pdf","citationCount":"0","resultStr":"{\"title\":\"Injection Site Reaction to Extended-Release Buprenorphine (Sublocade<sup>®</sup>) for Opioid Use Disorder Fourteen Days after Administration.\",\"authors\":\"Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, Jaya Sri Konakanchi, Gregory Maggio, Roopa Sethi\",\"doi\":\"10.17161/kjm.vol15.17931\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"302 Injection Site Reaction to ExtendedRelease Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration Elizabeth Weesner1, Hosain Ghassemi1, Iryna Salapenka, M.D.2, Jaya Sri Konakanchi, MBBS1, Gregory Maggio, D.O.2, Roopa Sethi, M.D.2 1University of Kansas School of Medicine, Kansas City, KS 2University of Kansas Health System, Kansas City, KS Department of Psychiatry and Behavioral Sciences Received April 21, 2022; Accepted for publication May 25, 2022; Published online Aug. 22, 2022 https://doi.org/10.17161/kjm.vol15.17931\",\"PeriodicalId\":17991,\"journal\":{\"name\":\"Kansas Journal of Medicine\",\"volume\":\" \",\"pages\":\"302-304\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/34/15-302.PMC9409986.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kansas Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17161/kjm.vol15.17931\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kansas Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17161/kjm.vol15.17931","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration.
302 Injection Site Reaction to ExtendedRelease Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration Elizabeth Weesner1, Hosain Ghassemi1, Iryna Salapenka, M.D.2, Jaya Sri Konakanchi, MBBS1, Gregory Maggio, D.O.2, Roopa Sethi, M.D.2 1University of Kansas School of Medicine, Kansas City, KS 2University of Kansas Health System, Kansas City, KS Department of Psychiatry and Behavioral Sciences Received April 21, 2022; Accepted for publication May 25, 2022; Published online Aug. 22, 2022 https://doi.org/10.17161/kjm.vol15.17931
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
